QCG
RVNC

Quadrant Capital Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Quadrant Capital Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-434
Closed -$2.25K – 2811
2024
Q3 		$2.25K Buy
+434
New +$2.16K ﹤0.01% 2481
2024
Q2 		– Sell
-400
Closed -$1.97K – 2780
2024
Q1 		$1.97K Sell
400
-198
-33% -$1.17K ﹤0.01% 2516
2023
Q4 		$5.26K Buy
598
+455
+318% +$3.73K ﹤0.01% 2266
2023
Q3 		$1.64K Sell
143
-22
-13% -$423 ﹤0.01% 2434
2023
Q2 		$4.18K Buy
165
+7
+4% +$218 ﹤0.01% 2248
2023
Q1 		$5.09K Sell
158
-2
-1% -$62 ﹤0.01% 2235
2022
Q4 		$2.95K Sell
160
-56
-26% -$1.28K ﹤0.01% 2321
2022
Q3 		$6K Hold
216
– – ﹤0.01% 2109
2022
Q2 		$3K Sell
216
-41
-16% -$631 ﹤0.01% 2161
2022
Q1 		$5K Sell
257
-60
-19% -$910 ﹤0.01% 1943
2021
Q4 		$5K Buy
317
+204
+181% +$3.4K ﹤0.01% 1913
2021
Q3 		$3K Buy
113
+5
+5% +$143 ﹤0.01% 2086
2021
Q2 		$3K Sell
108
-110
-50% -$3.17K ﹤0.01% 2054
2021
Q1 		$6K Hold
218
– – ﹤0.01% 1752
2020
Q4 		$6K Hold
218
– – ﹤0.01% 1662
2020
Q3 		$5K Hold
218
– – ﹤0.01% 1581
2020
Q2 		$5K Sell
218
-6,802
-97% -$134K ﹤0.01% 1696
2020
Q1 		$104K Buy
7,020
+9
+0.1% +$186 0.02% 570
2019
Q4 		$111K Hold
7,011
– – 0.01% 915
2019
Q3 		$89K Buy
+7,011
New +$85.8K 0.01% 933
2019
Q2 		– Sell
-1,478
Closed -$23K – 2415
2019
Q1 		$23K Buy
1,478
+1,375
+1,335% +$23.8K ﹤0.01% 1506
2018
Q4 		$2K Hold
103
– – ﹤0.01% 1962
2018
Q3 		$2K Hold
103
– – ﹤0.01% 1930
2018
Q2 		$2K Hold
103
– – ﹤0.01% 1939
2018
Q1 		$3K Hold
103
– – ﹤0.01% 1751
2017
Q4 		$3K Hold
103
– – ﹤0.01% 1701
2017
Q3 		$2K Hold
103
– – ﹤0.01% 1864
2017
Q2 		$2K Hold
103
– – ﹤0.01% 1630
2017
Q1 		$2K Buy
+103
New +$2.12K ﹤0.01% 1678

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Quadrant Capital Group's RVNC Position: Q4 2024 in Review

Quadrant Capital Group sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 434 shares — an estimated $2.25K sold.

Quadrant Capital Group first reported a position in RVNC in Q1 2017 and held it in 29 quarters. The position peaked at $111K in Q4 2019. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Quadrant Capital Group reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 434 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $2.25K.
  • Quadrant Capital Group first reported a position in Revance Therapeutics, Inc. in Q1 2017 and held it in 29 quarters.
  • Quadrant Capital Group's Revance Therapeutics, Inc. position peaked at $111K in Q4 2019.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Quadrant Capital Group's 13F filing for Q4 2024, filed 13 Feb 2025.